title: Association between skin and joint involvement in patients with psoriatic arthritis treated with adalimumab: analysis of data from a German non-interventional study.
abstract: BACKGROUND
  The association between skin and joint manifestations in patients with psoriatic arthritis (PsA) requires further characterization.
  
  
  OBJECTIVE
  We evaluated the association between severity of skin disease and joint involvement and the effectiveness and safety of adalimumab in PsA patients by baseline psoriasis severity.
  
  
  METHODS
  Descriptive statistics and regression analyses were used to evaluate data from 1,918 PsA patients starting adalimumab treatment. Subgroup analyses were conducted on patients empirically grouped by baseline target lesion score as a marker of psoriasis severity.
  
  
  RESULTS
  Psoriasis severity was not associated with joint manifestations at baseline or after 12 months of treatment. All subgroups showed improvements in skin and joints during therapy, and adalimumab was safe and well tolerated in all subgroups.
  
  
  CONCLUSIONS
  The severity of skin manifestations does not correlate with the severity of joint disease in PsA patients; even patients with mild skin disease may have extensive musculoskeletal involvement.
authors: Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein Campus Lübeck, Lübeck, Germany.
authors: Diamant
authors: D
authors: Thaçi
authors: Frank
authors: F
authors: Behrens
authors: Gerd
authors: G
authors: Greger
authors: Harald
authors: H
authors: Burkhardt
authors: Holger
authors: H
authors: Gnann
authors: Rudolf
authors: R
authors: Schopf
authors: Bianca Maria
authors: BM
authors: Wittig
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001168:Arthritis / Q000150:complications; D015535:Arthritis, Psoriatic / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D005858:Germany; D006801:Humans; D007596:Joints; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications; D012867:Skin
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab